AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33438206
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of medications with limited benefit in hospice patients (cancer and non-cancer diagnoses)
Trial: 33438206
Drug: Prescribing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribing oral anticoagulants in the emergency department
Trial: 33438206
Drug: Conducting electronic
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conducting electronic medication reconciliation
Trial: 33438206
Drug: Intensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of antihypertensive medications
Trial: 33199081
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of continuous wave CO2 laser and fractional ablative CO2 laser (Group 1)
Trial: 33078725
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam administered by parents
Trial: 33078725
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam administered by doctors
Trial: 32252049
Drug: Lactofem oral
RxNorm normalized name: citronellene lactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactofem oral probiotic capsule (500 mg daily for 2 months)
Trial: 35470105
Drug: Cholecalciferol (50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (50,000 IU weekly for 8 weeks)
Trial: 35470105
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (identical for 8 weeks)
Trial: 34688374
Drug: Toripalimab monotherapy
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab monotherapy (n=17)
Trial: 34335740
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (0.3 mg/kg bolus after induction, followed by 0.2 mg/kg/hr infusion for up to 24 hours)
Trial: 32012051
Drug: Twice-a-day pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day pain reporting
Trial: 35352134
Drug: High inflammation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High inflammation group (CRP ≥ 2.0 mg/L)
Trial: 35352134
Drug: Low inflammation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low inflammation group (CRP < 2.0 mg/L)
Trial: 36195807
Drug: oral voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral voriconazole (inhibitor)
Trial: 36195807
Drug: intravenous voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous voriconazole (inhibitor)
Trial: 32127545
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration (standard nasal spray)
Trial: 32127545
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration (nebulizer)
Trial: 32188915
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg/day for 7 days
Trial: 33434451
Drug: 4 monthly
RxNorm normalized name: tobramycin 28 MG inhalation powder 224 Monthly Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 monthly videoconference‐tailored coaching sessions with an advanced practice nurse or social worker, participation in patient appointments via videoconference, access to a website designed for DCGs.
Trial: 32933498
Drug: Preoperative induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative induction chemotherapy (2 cycles of FLOT: 5‐FU, leucovorin, oxaliplatin, docetaxel) followed by preoperative radiochemotherapy (oxaliplatin weekly, 5‐FU plus concurrent fractioned radiotherapy to a dose of 45 Gy)
Trial: 32933498
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy alone (4 cycles of FLOT)
Trial: 32933498
Drug: Combined chemotherapy/radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy/radiochemotherapy treatment
Trial: 32933498
Drug: Preoperative induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative induction chemotherapy (2 cycles of FLOT) followed by preoperative radiochemotherapy
Trial: 32933498
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with FLOT alone
Trial: 33528516
Drug: 10-mg/d Vericiguat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg/d Vericiguat
Trial: 33528516
Drug: 15-mg/d Vericiguat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg/d Vericiguat
Trial: 34341196
Drug: Manual separation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual separation followed by topical antibiotic ointment application for 1 week with local hygiene
Trial: 35917993
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) administered prior to initial acquisition of a predictive learning task
Trial: 34043103
Drug: Eribulin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin as first- or second-line chemotherapy
Trial: 34110839
Drug: TAU-only (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU-only (treatment as usual)
Trial: 33667194
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone (T)
Trial: 33667194
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor letrozole (Lz)
Trial: 33619855
Drug: Local infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infusion of ropivacaine
Trial: 33789432
Drug: Dry Needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Needling Combined With Guideline‐Based Physical Therapy
Trial: 33789432
Drug: Guideline‐Based Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline‐Based Physical Therapy
Trial: 34600589
Drug: IL-6 receptor
RxNorm normalized name: Humanised anti-IL-6 receptor monoclonal antibody
DrugBank: Satralizumab (DB15762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IL-6 receptor antagonists (IL-6RAs)
Trial: 34600589
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IL-6RAs and steroids)
Trial: 32339359
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; n=31)
Trial: 33724264
Drug: CRT-D (Cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D (Cardiac Resynchronization and Defibrillator Therapy)
Trial: 33068691
Drug: EX +
RxNorm normalized name: Freeflex + Transfer Adapter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX + 500 mg/day resveratrol (EX500)
Trial: 33068691
Drug: EX +
RxNorm normalized name: Freeflex + Transfer Adapter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX + 1000 mg/day resveratrol (EX1000)
Trial: 32247660
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (10 mg/kg) plus acetaminophen (15 mg/kg)
Trial: 33197226
Drug: Continued chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued chemotherapy in exploratory analysis of PD-L1-positive population (n = 137)
Trial: 35072758
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg daily) + Sertraline (100 mg daily)
Trial: 35072758
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Sertraline (100 mg daily)
Trial: 34708642
Drug: Qingre Huatan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingre Huatan formulae + Western Medicine
Trial: 34708642
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western Medicine only
Trial: 34988730
Drug: Intradermal tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal tranexamic acid injection combined with low fluence Q-switched Nd:YAG laser
Trial: 34988730
Drug: Intradermal tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal tranexamic acid injection alone
Trial: 33197270
Drug: 5% ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% ibuprofen gel
Trial: 33197270
Drug: 0.025% capsaicin
RxNorm normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% capsaicin cream
Trial: 33197270
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of ibuprofen and capsaicin
Trial: 32635181
Drug: Vitamin B‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B‐6 (50 mg pyridoxine/d)
Trial: 32635181
Drug: GSH (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSH (500 mg/d)
Trial: 35971130
Drug: Everyday Life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everyday Life Rehabilitation (ELR) plus treatment as usual (TAU)
Trial: 33551217
Drug: High fructose
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fructose diet (HiFruD, 1.4 g kg−1 day−1 fructose + 0.1 g kg−1 day−1 glucose)
Trial: 33551217
Drug: Low fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low fructose diet (LoFruD, <10 g/d)
Trial: 33185824
Drug: Harm Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harm Reduction Treatment for Alcohol (HaRT‐A)
Trial: 32184026
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of ready-to-use therapeutic food (RUTF)
Trial: 32184026
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of ready-to-use therapeutic food (RUTF)
Trial: 35896378
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg once daily for 2 weeks
Trial: 35896378
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg once daily for 6 weeks
Trial: 33658293
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intramuscular respiratory syncytial virus (RSV) F‐protein vaccine
Trial: 32113309
Drug: Acoustic quantification
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic quantification of oral diadochokinetic (DDK) task using [ka] sequences
Trial: 32113309
Drug: Acoustic quantification
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic quantification of oral diadochokinetic (DDK) task using [pa] sequences
Trial: 32113309
Drug: Acoustic quantification
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic quantification of oral diadochokinetic (DDK) task using [ta] sequences
Trial: 33152142
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG treatment
Trial: 32470975
Drug: Vitamin B-12
RxNorm normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B-12 supplementation (50 μg daily orally)
Trial: 34469628
Drug: Medicines Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicines Management Optimisation Review (MOR)
Trial: 32988598
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D therapy (approximately 1,200 IU daily)
Trial: 35857130
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg xanthohumol
Trial: 35435296
Drug: Trimax-360 Serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimax-360 Serum applied twice a day for 98 days
Trial: 32514751
Drug: CBD 10
RxNorm normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 1000MG COOL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 10 mg/kg/day plus current clinical management (CCM)
Trial: 32514751
Drug: CBD 20
RxNorm normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 20 mg/kg/day plus CCM
Trial: 32513564
Drug: SC-003 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC-003 at 0.3 mg/kg and 0.2 mg/kg
Trial: 32513564
Drug: SC-003 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC-003 monotherapy or in combination with budigalimab
Trial: 36255239
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g CAS+IMD
Trial: 36255239
Drug: 8.0 g
RxNorm normalized name: PERACETIC ACID 8.0 g in 4000 mL TOPICAL LIQUID [Peraflu D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.0 g CAS+IMD
Trial: 36255239
Drug: CAS+IMD combined-dose
RxNorm normalized name: CA-170
DrugBank: CA-170 (DB15772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAS+IMD combined-dose
Trial: 34121357
Drug: Acetaminophen syrup
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen syrup (320 mg/10 ml)
Trial: 34121357
Drug: Ibuprofen syrup
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen syrup (200 mg/10 ml)
Trial: 32079623
Drug: Avelumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab (10 mg/kg, 2 weekly for 24 weeks)
Trial: 32079623
Drug: Standard fluoropyrimidine‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluoropyrimidine‐based chemotherapy (capecitabine, oxaliplatin for 12 weeks or capecitabine for 24 weeks)
Trial: 33626889
Drug: Remote hemodynamic-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote hemodynamic-guided pharmacotherapy (treatment)
Trial: 35296293
Drug: Non-surgical spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical spinal decompression therapy (NSD) in addition to routine physical therapy
Trial: 35799556
Drug: Clonidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (300 mcg)
Trial: 32716652
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training (PFMT) + game therapy (GT)
Trial: 32716652
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PFMT and PFMT+GT)
Trial: 32334045
Drug: Riboflavin supplementation
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin supplementation (1.6 mg/day)
Trial: 32334045
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (MTHFR CC genotype)
Trial: 35168622
Drug: Emergency Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency Medicine Palliative Care Access (EMPallA) trial
Trial: 35377948
Drug: Neoadjuvant durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant durvalumab plus chemotherapy
Trial: 33288437
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (100 μg/24 h) with intermittent micronized progesterone
Trial: 35654480
Drug: Alfentanil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (10 µg/kg before intubation) + sevoflurane anesthesia
Trial: 32729619
Drug: gaboxadol 15
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gaboxadol 15 mg
Trial: 32526195
Drug: Baloxavir (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baloxavir (40 mg for patients <80 kg, 80 mg for patients ≥80 kg)
Trial: 33630393
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g)
Trial: 32810921
Drug: Digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital cognitive behavioural therapy for insomnia (Sleepio)
Trial: 34551104
Drug: Middle-dose vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle-dose vaccine
Trial: 34551104
Drug: Ad5-vectored COVID-19
RxNorm normalized name: covid-19, viral vector, non-replicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-vectored COVID-19 vaccine (single dose in children and adolescents)
Trial: 34551104
Drug: Ad5-vectored COVID-19
RxNorm normalized name: covid-19, viral vector, non-replicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-vectored COVID-19 vaccine (two doses in adults)
Trial: 34287975
Drug: Fractional RF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional RF treatment with 1.0‐mm long × 0.15‐mm diameter ultrathin electrode tips
Trial: 32844454
Drug: Lanolin-containing test
RxNorm normalized name: Lanolin
DrugBank: Lanolin (DB11112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanolin-containing test creams applied twice daily for 4 weeks on arms with irritant dermatitis
Trial: 32844454
Drug: Lanolin-free cream
RxNorm normalized name: Lanolin
DrugBank: Lanolin (DB11112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanolin-free cream base applied twice daily for 4 weeks on arms with irritant dermatitis
Trial: 35276700
Drug: Graded exposure
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded exposure treatment (GET)
Trial: 34051122
Drug: Tapentadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol (50 mg twice daily)
Trial: 34051122
Drug: Oxycodone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (10 mg twice daily)
Trial: 33444780
Drug: Optimised adherence
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised adherence treatment (post-programme)
Trial: 36251383
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (6 mg·kg ‐1 body weight)
Trial: 34037271
Drug: RO7062931 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7062931 at 3.0 mg/kg every week (QW)
Trial: 34037271
Drug: RO7062931 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7062931 at 0.5, 1.5, or 3.0 mg/kg every month for a total of 2 doses
Trial: 34037271
Drug: RO7062931 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7062931 at 3.0 mg/kg every 2 weeks, 3.0 mg/kg every week (QW), or 4.0 mg/kg QW
Trial: 36027721
Drug: idursulfase-IT 10
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: idursulfase-IT 10 mg
Trial: 33811746
Drug: First-line platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line platinum-based chemotherapy (carboplatin/paclitaxel)
Trial: 32150263
Drug: D0 rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: D0 rituximab infusion (500 mg)
Trial: 32150263
Drug: D0+D14 rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: D0+D14 rituximab infusion (500 mg)